Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT03363100 · ClinicalTrials.gov registry record · NA

Diabetes Coaching Program for Medicare Advantage Members With Type 2 Diabetes - Impact on A1c

A NA study of Diabetes Mellitus, Type 2, sponsored by Evidation Health.

Completed
Registry status
NA
Development phase
624
Enrollment target
1
Study location

NCT03363100 is a NA study of Diabetes Mellitus, Type 2 that has completed, run by Evidation Health. The registered enrollment target is 624 participants, below the 4,484-participant average among 348 other Diabetes Mellitus, Type 2 trials with a reported enrollment target (86% lower). The trial reports 1 study location across 1 state.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT03363100, a NA study of Diabetes Mellitus, Type 2, has completed, sponsored by Evidation Health.

COMPLETED
Registry status
NA
Development phase
624 participants
Enrollment target
1
Study location

Study Summary

The Diabetes Coaching Program for Medicare Advantage Members with Type 2 Diabetes - Impact on A1c trial is a 26-week long, prospective, intent-to-treat, 2-arm randomized controlled trial that aims to evaluate the impact of the Digital Health Partnership on A1c levels for individuals with uncontrolled Type 2 diabetes.

Conditions Studied

Interventions

  • BEHAVIORAL Digital health Partnership program

Study Locations (1)

California

  • Evidation Health - San Mateo

Trial Details

FieldValue
Enrollment Target 624 participants
Start Date 2017-12-05
Est. Completion 2019-02-23
Phase NA

Sponsor

Evidation Health

12 total trials

What the Registry Record Tells You About NCT03363100

The ClinicalTrials.gov registry entry for NCT03363100 describes a study currently listed as completed, categorized as NA. The registered enrollment target is 624 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 4,484-participant average among 348 other Diabetes Mellitus, Type 2 trials with a reported enrollment target (86% lower). The listed sponsor is Evidation Health, which has 12 total studies on file at ClinicalTrials.gov.

The record links to 1 condition, with Diabetes Mellitus, Type 2 appearing as the primary indexed condition, and to 1 intervention - of which Digital health Partnership program is the first listed.

NCT03363100 reports 1 study location spanning 1 distinct geographic area - top geographies include California.

Frequently Asked Questions

What is clinical trial NCT03363100 about?

NCT03363100 is a clinical study titled "Diabetes Coaching Program for Medicare Advantage Members With Type 2 Diabetes - Impact on A1c". The Diabetes Coaching Program for Medicare Advantage Members with Type 2 Diabetes - Impact on A1c trial is a 26-week long, prospective, intent-to-treat, 2-arm randomized controlled trial that aims to evaluate the impact of the Digital Health Partnership on A1c levels for individuals with uncontrolle...

What is the current status of trial NCT03363100?

This trial is currently completed. It is a NA study. The enrollment target is 624 participants. The study started on 2017-12-05. Estimated completion is 2019-02-23.

What conditions does trial NCT03363100 study?

This clinical trial studies the following conditions: Diabetes Mellitus, Type 2.

What interventions are being tested in trial NCT03363100?

The interventions under investigation include: Digital health Partnership program (BEHAVIORAL).

Who is sponsoring clinical trial NCT03363100?

This trial is sponsored by Evidation Health, which has 12 total clinical trials registered on ClinicalTrials.gov.

Where is trial NCT03363100 being conducted?

This trial has 1 study location across California. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.

Similar trials for Diabetes Mellitus, Type 2

Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.

Data sourced from official public datasets. See our methodology for details. Retrieved and formatted by PlainTrial

Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.